OmniAb (NASDAQ:OABI) Trading Up 1.4% – Still a Buy?

Posted by Geri Gentry on Jul 16th, 2026

OmniAb, Inc. (NASDAQ:OABI – Get Free Report)’s stock price traded up 1.4% on Tuesday . The stock traded as high as $2.21 and last traded at $2.14. Approximately 545,976 shares were traded during trading, a decline of 12% from the average session volume of 620,178 shares. The stock had previously closed at $2.11.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of OmniAb from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 18th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $3.00.

Check Out Our Latest Stock Analysis on OmniAb

OmniAb Price Performance

The firm has a 50-day simple moving average of $2.32 and a two-hundred day simple moving average of $1.94. The company has a market cap of $295.36 million, a PE ratio of -4.43 and a beta of 0.43.

OmniAb (NASDAQ:OABI – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.04. The business had revenue of $14.43 million for the quarter, compared to the consensus estimate of $5.60 million. OmniAb had a negative return on equity of 20.31% and a negative net margin of 187.59%. Equities research analysts forecast that OmniAb, Inc. will post -0.39 EPS for the current year.

Institutional Investors Weigh In On OmniAb

Hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC boosted its position in OmniAb by 11.1% during the first quarter. Renaissance Technologies LLC now owns 269,600 shares of the company’s stock worth $423,000 after acquiring an additional 26,900 shares during the last quarter. Sei Investments Co. lifted its stake in shares of OmniAb by 41.3% during the 1st quarter. Sei Investments Co. now owns 60,578 shares of the company’s stock worth $95,000 after purchasing an additional 17,718 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of OmniAb by 92.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 21,721 shares of the company’s stock worth $35,000 after purchasing an additional 10,438 shares during the period. Osaic Holdings Inc. boosted its holdings in shares of OmniAb by 214.4% during the second quarter. Osaic Holdings Inc. now owns 14,247 shares of the company’s stock worth $25,000 after purchasing an additional 9,716 shares during the last quarter. Finally, Corient Private Wealth LLC acquired a new stake in shares of OmniAb during the second quarter worth $53,000. 72.08% of the stock is owned by institutional investors and hedge funds.

About OmniAb

(Get Free Report)

OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.